Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M

Vivani Medical, Inc.

Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.
Full-year 2023 net loss $25.7M vs $13.9M in 2022; R&D expenses rose 20% to $17.0M.
Positive preclinical data: NPM-115 (exenatide) showed ~20% weight loss in obese mice, comparable to semaglutide.
Daniel Bradbury appointed to Board; led Amylin's approval of once-weekly GLP-1 Bydureon.
Anticipates NPM-115 IND filing in H2 2024 and NPM-119 clinical hold response in H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.